Sector News

AstraZeneca Non-Executive Director Bruce Burlington to retire

August 17, 2017
Life sciences

AstraZeneca PLC on Wednesday said Non-Executive Director Bruce Burlington will retire from the board on August 31.

The FTSE 100-listed pharmaceutical said Burlington, who joined the board in 2010, will also step down as a member of the audit committee, the nomination and governance committee and from his role as chairman of the science committee.

Chairman Leif Johansson said: “Bruce has been an exemplary director who has made a significant contribution to the board’s work over many years. We have valued his insightful and frank participation as a board member, and chairman of the science committee during a period of innovation-led transformation at AstraZeneca.

“His diligence and commitment to the work of the audit committee and the nomination and governance committee should also be acknowledged.”

By Maryam Cockar

Source: Alliance News

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”